Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Melinta Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Venatorx and Melinta Update on U.S. NDA for Cefepime-Taniborbactam
Details : VNRX-5022 (cefepime) & taniborbactam, an investigational beta-lactam/beta-lactamase inhibitor, is under development for treating complicated urinary tract infections and bacterial pneumonia in adults.
Brand Name : VNRX-5022
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2024
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Melinta Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Menarini
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Venatorx and Menarini Enter Commercial Agreement for Cefepime-Taniborbactam
Details : Menarini will acquire rights to commercialize VNRX-5022/VNRX-5133 (cefepime-taniborbactam), an investigational antibiotic for complicated urinary tract infections, in 96 countries.
Brand Name : VNRX-5022
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 09, 2024
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Menarini
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Melinta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adu...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Melinta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ceftibuten-ledaborbactam Etzadroxil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : BARDA
Deal Size : $167.0 million
Deal Type : Funding
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
Details : The funding will be used to support the development of oral antibiotic VNRX-7145 (ceftibuten-ledaborbactam etzadroxil) for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Ceftibuten-ledaborbactam Etzadroxil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : BARDA
Deal Size : $167.0 million
Deal Type : Funding
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic combination being developed for the treatment of complicated urinary tract infections.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2023
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Venatorx Pharmaceuticals to Present at IDWeek 2022
Details : VNRX-5133 (cefepime), a fourth-generation cephalosporin, is a widely used beta-lactam (BL) antibiotic with more than two decades of proven safety and clinical utility against susceptible gram-negative and gram-positive bacteria.
Brand Name : VNRX-5133
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2022
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Taniborbactam,Cefepime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Series C Financing
Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund
Details : Proceeds from financing will be used to support Venatorx as it advances its novel antibacterial VNRX-5133, through drug development process, including NDA with the U.S. FDA for cefepime-taniborbactam for the treatment of complicated urinary tract infecti...
Brand Name : VNRX-5133
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 04, 2022
Lead Product(s) : Taniborbactam,Cefepime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Series C Financing
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cefepime-taniborbactam met primary efficacy endpoint of statistical non-inferiority to meropenem in microbiological intent-to-treat population in 70.0% of cefepime-taniborbactam treated patients and 58.0% of meropenem treated patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2022
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Everest Medicines
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Venatorx Pharmaceuticals to Present Data on Cefepime-Taniborbactam at IDWeek 2020
Details : In a 7-day HFIM with humanized exposures and high initial inoculums, Cefepime (FEP)-Taniborbactam (TAN) provided sustained bactericidal activity against multidrug-resistant Enterobacterales and P. aeruginosa strains and suppressed growth of resistant sub...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2020
Lead Product(s) : Cefepime,Taniborbactam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Non-beta-lactam antibiotic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : NIAID
Deal Size : $44.2 million
Deal Type : Funding
Details : Funding aims to advance a novel series of Penicillin Binding Protein (PBP) Inhibitors targeting multi-drug resistant (MDR) Acinetobacter baumannii through Phase 1 clinical testing.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 27, 2020
Lead Product(s) : Non-beta-lactam antibiotic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : NIAID
Deal Size : $44.2 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?